Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Precision BioSciences Inc...

    NASDAQ: DTIL · Real-Time Price · USD
    4.70
    -0.20 (-4.08%)
    At close: Jun 18, 2025, 3:59 PM
    4.82
    2.55%
    After-hours: Jun 18, 2025, 06:58 PM EDT
    -4.08%
    Bid 4.5
    Market Cap 51.99M
    Revenue (ttm) 51.14M
    Net Income (ttm) -21.99M
    EPS (ttm) -2.87
    PE Ratio (ttm) -1.64
    Forward PE -1.08
    Analyst Buy
    Ask 5
    Volume 166,210
    Avg. Volume (20D) 139,822
    Open 4.91
    Previous Close 4.90
    Day's Range 4.46 - 4.91
    52-Week Range 3.61 - 11.09
    Beta 1.47

    About DTIL

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol DTIL
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for DTIL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 months ago
    +23.77%
    Precision BioSciences shares are trading higher af... Unlock content with Pro Subscription
    2 months ago
    -11%
    Precision BioSciences shares are trading lower following a Q4 EPS miss.
    news image

    1 month ago · zacks.com

    Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

    Precision BioSciences (DTIL) came out with a quarterly loss of $2.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.35 per share a year ago.

    news image

    1 month ago · businesswire.com

    Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

    DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...

    news image

    1 month ago · businesswire.com

    Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

    DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...

    news image

    1 month ago · businesswire.com

    Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

    DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...

    news image

    1 month ago · businesswire.com

    Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

    DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...

    news image

    1 month ago · businesswire.com

    Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

    DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...

    news image

    1 month ago · businesswire.com

    Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...

    news image

    2 months ago · zacks.com

    DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

    Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.

    news image

    2 months ago · businesswire.com

    Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

    DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...

    news image

    2 months ago · businesswire.com

    Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

    DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...

    Add to Watchlist